Last reviewed · How we verify
NBP608 (Mid Potency)
NBP608 is a mid-potency corticosteroid that reduces inflammation by binding to glucocorticoid receptors and suppressing immune and inflammatory responses.
NBP608 is a mid-potency corticosteroid that reduces inflammation by binding to glucocorticoid receptors and suppressing immune and inflammatory responses. Used for Inflammatory skin conditions (dermatitis, eczema, psoriasis), Allergic and inflammatory disorders.
At a glance
| Generic name | NBP608 (Mid Potency) |
|---|---|
| Sponsor | SK Bioscience Co., Ltd. |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Biologic |
| Therapeutic area | Dermatology, Immunology, Inflammation |
| Phase | Phase 3 |
Mechanism of action
As a mid-potency topical or systemic corticosteroid, NBP608 works by activating glucocorticoid receptors in immune cells and inflamed tissues, leading to decreased production of pro-inflammatory cytokines and reduced recruitment of immune cells. This mechanism makes it suitable for treating inflammatory and allergic conditions where moderate anti-inflammatory potency is desired.
Approved indications
- Inflammatory skin conditions (dermatitis, eczema, psoriasis)
- Allergic and inflammatory disorders
Common side effects
- Skin atrophy
- Telangiectasia
- Striae
- Local irritation or burning
Key clinical trials
- SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years (PHASE3)
- Safety Study of NBP608 in Healthy Adult Volunteers (PHASE1)
- The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |